Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX Summary
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 3 | $57.5 | $40.59 | -$16.91 | -29.41% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 129 | $2,445.84 | $1,949.83 | -$496.01 | -20.28% |
| NA Nizar Araji National Bank Of Canada /FI/ | 6,150 | $73,486.71 | $85,854 | $12,367.29 | 16.83% |
 John H. Burbank III Passport Capital LLC | 32.79M | $423.88M | $437.7M | $13.81M | 3.26% |
 QVT Financial QVT Financial LP | 360,524 | $2.81M | $4.81M | $2M | 71.15% |
Summit Therapeutics Inc. (SMMT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Summit Therapeutics Inc. ever had a stock split?
Summit Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert W. Duggan CEO | NASDAQ (NMS) Exchange | 86627T108 CUSIP |
| US Country | 265 Employees | - Last Dividend | - Last Split | 5 Mar 2015 IPO Date |
Overview
Summit Therapeutics Inc. stands as a pioneering entity within the biopharmaceutical industry, dedicating its efforts toward the discovery, development, and commercialization of innovative therapeutic solutions. With a mission to cater to the needs of patients, physicians, caregivers, and society at large, the company has established a significant presence in both the United States and the United Kingdom. Since its inception in 2003, with its headquarters in Miami, Florida, Summit Therapeutics has been at the forefront of addressing some of the most challenging medical conditions by advancing a pipeline of promising drug candidates. The collaboration and license agreement with Akeso, Inc. and its affiliates specifically for the development and commercialization of ivonescimab highlights the company's strategy to leverage partnerships in realizing its vision.
Products and Services
- Ivonescimab
- SMT-738
This lead development candidate exemplifies Summit Therapeutics' focus on groundbreaking immunotherapy approaches. Ivonescimab is a bispecific antibody designed to block PD-1, enhancing the immune system's ability to fight cancer, while also targeting anti-angiogenesis, which is the process of cutting off the blood supply to tumors. This dual mechanism of action positions ivonescimab as a potentially powerful treatment for various cancers, reflecting Summit's commitment to advancing cancer treatment.
Under its portfolio of anti-infectives, Summit Therapeutics is developing SMT-738, a novel class of precision antibiotics aimed at combating multidrug-resistant infections, with a primary focus on tackling carbapenem-resistant Enterobacteriaceae (CRE) infections. The increasing prevalence of antibiotic-resistant infections represents a significant threat to public health, and SMT-738 is at the forefront of Summit's effort to develop effective treatments for these challenging conditions. By focusing on precision antibiotics, Summit aims to deliver treatments that are not only effective against pathogens but also minimize the impact on the body's beneficial bacteria, thus offering a groundbreaking approach to tackling antibiotic resistance.
